Pharmacokinetic considerations in seasonal malaria chemoprevention

Journal article : Review

African children under 5 years of age bear the main burden of global malaria mortality. Seasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine (SP) plus amodiaquine (AQ) given monthly during the rainy season is a highly effective malaria intervention for children aged between 3 months and 5 years living in the Sahel region, a region of intense but seasonal malaria transmission. This intervention is now being considered for other regions of Africa where malaria parasites are more drug resistant. Dihydroartemisinin-piperaquine (DP), an artemisinin-based combination therapy (ACT), has proved to be highly effective and well tolerated in intermittent preventive treatment in pregnant women and children. This combination may be a suitable alternative for SMC. Understanding the safety, pharmacokinetic and pharmacodynamic properties of antimalarial combination therapies is crucial in optimising dosing.

Authors: Chotsiri, P; White, NJ; Tarning, J

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: Cell Press
• Journal: Trends in Parasitology
• Volume: 38
• Issue: 8
• Pages: 673-682
• Publication date: 2022-06-07
• Acceptance date: 2022-05-10
• DOI: 10.1016/j.pt.2022.05.003
• EISSN: 1471-5007
• ISSN: 1471-4922
• Pmid: 35688778
• Language: English
• Keywords: antimalarials; FFR; chemoprevention; amodiaquine; drug therapy; infant; combination; humans; child; drug combinations; preschool; seasons; sulfadoxine; pregnancy; malaria; pyrimethamine; female
• Subtype: Review